Fezolinetant in the treatment of vasomotor symptoms associated with menopause

References

• Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006 Jul;96(7):1226–1235.
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531–539.
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013 Aug;34(3):211–227.
   PubMed Web of Science ®Google Scholar
• Williams RE, Kalilani L, DiBenedetti DB, et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007 Dec 20;58(4):348–358.
   PubMed Web of Science ®Google Scholar
• Whiteley J, DiBonaventura M, Wagner JS, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt). 2013 Nov;22(11):983–990.
   PubMed Web of Science ®Google Scholar
• Williams RE, Levine KB, Kalilani L, et al. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009 Feb 20;62(2):153–159.
   PubMed Web of Science ®Google Scholar
• Thurston RC, Bromberger JT, Joffe H, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause. 2008 Sep-Oct;15(5):841–847.
   PubMed Web of Science ®Google Scholar
• Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the study of women’s health across the Nation. Obstet Gynecol Clin North Am. 2011 Sep;38(3):489–501.
   PubMed Web of Science ®Google Scholar
• Worsley R, Bell RJ, Gartoulla P, et al. Moderate-severe vasomotor symptoms are associated with moderate-severe depressive symptoms. J Womens Health (Larchmt). 2017 Jul;26(7):712–718.
   PubMed Web of Science ®Google Scholar
• Whiteley J, Wagner JS, Bushmakin A, et al. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013 May;20(5):518–524.
   PubMed Web of Science ®Google Scholar
• Sarrel P, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015 Mar;22(3):260–266.
   PubMed Web of Science ®Google Scholar
• The NAMS Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017 Jul;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975–4011.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016 Sep;91:153–155.
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins - Gynecology. ACOG practice bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014 Jan;123(1):202–216.
   PubMed Web of Science ®Google Scholar
• Okano H, Higuchi T, Kurabayashi T, et al. Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women’s Health 2017 guidelines for hormone replacement therapy. J Obstet Gynaecol Res. 2018 Aug;44(8):1355–1368.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Sep 28;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000402.
   PubMed Web of Science ®Google Scholar
• Pfizer Canada Inc. Complete prescribing information PREMARIN® Vaginal Cream 2018 [cited 2021 March 15]. Available from: https://www.pfizer.ca/sites/default/files/201806/Premarin_VC_PM_E_204671_07Jun2018.pdf
   Google Scholar
• Evorel® Sequi patient leaflet 2019 [cited 2021 March 15]. Available from: https://www.medicines.org.uk/emc/files/pil.10930.pdf
   Google Scholar
• Lumsden MA. The NICE Guideline - Menopause: diagnosis and management. Climacteric. 2016 Oct;19(5):426–429.
   PubMed Web of Science ®Google Scholar
• Bair YA, Gold EB, Zhang G, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women’s Health Across the Nation. Menopause. 2008 Jan-Feb;15(1):32–43.
   PubMed Web of Science ®Google Scholar
• Cumming GP, Currie H, Morris E, et al. The need to do better – Are we still letting our patients down and at what cost? Post Reprod Health. 2015 Jun;21(2):56–62.
   PubMedGoogle Scholar
• The North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015 Nov;22(11):1155–1172. quiz1173–1174.
   PubMed Web of Science ®Google Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014 Jan;94(1):265–301.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Baratelli C, Bironzo P, et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018 Apr;124:21–28.
   PubMed Web of Science ®Google Scholar
• Schank JR, Heilig M. Substance P and the neurokinin-1 receptor: the new CRF. Int Rev Neurobiol. 2017;136:151–175.
   PubMed Web of Science ®Google Scholar
• Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs. 2004 May;9(1):9–21.
   PubMedGoogle Scholar
• Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol. 2004 Apr;141(8):1249–1263.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Carlos Marvizon J. Neurokinin 3 receptors in the gut: a new target for the treatment of visceral pain? Gastroenterology. 1999 May;116(5):1250–1252.
   PubMed Web of Science ®Google Scholar
• Templeman L, Sellers DJ, Chapple CR, et al. Investigation of neurokinin-2 and -3 receptors in the human and pig bladder. BJU Int. 2003 Nov;92(7):787–792.
   PubMed Web of Science ®Google Scholar
• Crane LH, Williams MJ, Nimmo AJ, et al. Estrogen-dependent regulation of neurokinin 3 receptor-mediated uterine contractility in the rat. Biol Reprod. 2002 Nov;67(5):1480–1487.
   PubMed Web of Science ®Google Scholar
• Litman RE, Smith MA, Desai DG, et al. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J Clin Psychopharmacol. 2014 Apr;34(2):199–204.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Porter RA. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress. Future Med Chem. 2013 Sep;5(13):1525–1546.
   PubMed Web of Science ®Google Scholar
• Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet. 2009 Mar;41(3):354–358.
   PubMed Web of Science ®Google Scholar
• Hoveyda HR, Fraser GL, Roy MO, et al. Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I). J Med Chem. 2015 Apr 9;58(7):3060–3082.
   PubMed Web of Science ®Google Scholar
• Hoveyda HR, Fraser GL, Dutheuil G, et al. Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (part II). ACS Med Chem Lett. 2015 Jul 9;6(7):736–740.
   PubMed Web of Science ®Google Scholar
• Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015 Nov;156(11):4214–4225.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010 Dec;9(12):929–939.
   PubMed Web of Science ®Google Scholar
• Young RJ, Leeson PD. Mapping the efficiency and physicochemical trajectories of successful optimizations. J Med Chem. 2018 Aug 9;61(15):6421–6467.
   PubMed Web of Science ®Google Scholar
• Ridler K, Gunn RN, Searle GE, et al. Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. J Psychopharmacol. 2014 Mar;28(3):244–253.
   PubMed Web of Science ®Google Scholar
• Rance NE, Krajewski SJ, Smith MA, et al. Neurokinin B and the hypothalamic regulation of reproduction. Brain Res. 2010 Dec 10;1364:116–128.
   PubMed Web of Science ®Google Scholar
• Herbison AE. A simple model of estrous cycle negative and positive feedback regulation of GnRH secretion. Front Neuroendocrinol. 2020 Apr;57:100837.
   PubMed Web of Science ®Google Scholar
• Plant TM. A comparison of the neuroendocrine mechanisms underlying the initiation of the preovulatory LH surge in the human, Old World monkey and rodent. Front Neuroendocrinol. 2012 Apr;33(2):160–168.
   PubMed Web of Science ®Google Scholar
• Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep. 2015 Feb;16(5):8466.
   Google Scholar
• Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, et al. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19846–19851.
   PubMed Web of Science ®Google Scholar
• Dacks PA, Rance NE. Effects of estradiol on the thermoneutral zone and core temperature in ovariectomized rats. Endocrinology. 2010 Mar;151(3):1187–1193.
   PubMed Web of Science ®Google Scholar
• Okada M, Hayashi N, Kometani M, et al. Influences of ovariectomy and continuous replacement of 17beta-estradiol on the tail skin temperature and behavior in the forced swimming test in rats. Jpn J Pharmacol. 1997 Jan;73(1):93–96.
   PubMedGoogle Scholar
• Kobayashi T, Tamura M, Hayashi M, et al. Elevation of tail skin temperature in ovariectomized rats in relation to menopausal hot flushes. Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R863–R869.
   PubMed Web of Science ®Google Scholar
• Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991 May;128(5):2239–2247.
   PubMed Web of Science ®Google Scholar
• Rometo AM, Krajewski SJ, Voytko ML, et al. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab. 2007 Jul;92(7):2744–2750.
   PubMed Web of Science ®Google Scholar
• Rance NE, Bruce TR. Neurokinin B gene expression is increased in the arcuate nucleus of ovariectomized rats. Neuroendocrinology. 1994 Oct;60(4):337–345.
   PubMed Web of Science ®Google Scholar
• Mittelman-Smith MA, Krajewski-Hall SJ, McMullen NT, et al. Neurokinin 3 receptor-expressing neurons in the median preoptic nucleus modulate heat-dissipation effectors in the female rat. Endocrinology. 2015 Jul;156(7):2552–2562.
   PubMed Web of Science ®Google Scholar
• Padilla SL, Johnson CW, Barker FD, et al. A neural circuit underlying the generation of hot flushes. Cell Rep. 2018 Jul 10;24(2):271–277.
   PubMed Web of Science ®Google Scholar
• Krajewski-Hall SJ, Miranda Dos Santos F, McMullen NT, et al. Glutamatergic neurokinin 3 receptor neurons in the median preoptic nucleus modulate heat-defense pathways in female mice. Endocrinology. 2019 Apr 1;160(4):803–816.
   PubMed Web of Science ®Google Scholar
• Rance NE, McMullen NT, Smialek JE, et al. Postmenopausal hypertrophy of neurons expressing the estrogen receptor gene in the human hypothalamus. J Clin Endocrinol Metab. 1990 Jul;71(1):79–85.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Manson JE, Hohensee C, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the women’s health initiative study. Menopause. 2017 Mar;24(3):252–261.
   PubMed Web of Science ®Google Scholar
• MacLeay JM, Lehmer E, Enns RM, et al. Central and peripheral temperature changes in sheep following ovariectomy. Maturitas. 2003 Nov 20;46(3):231–238.
   PubMed Web of Science ®Google Scholar
• Tahara A, Takamatsu H, Ohtake A, et al. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats. Eur J Pharmacol 2021. In press https://doi.org/10.1016/j.ejphar.2021.174207.
   Google Scholar
• Fraser GL, Ramael S, Hoveyda HR, et al. The NK3 receptor antagonist ESN364 suppresses sex hormones in men and women. J Clin Endocrinol Metab. 2016 Feb;101(2):417–426.
   PubMed Web of Science ®Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992 Feb;166(2):740–745.
   PubMed Web of Science ®Google Scholar
• Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):5893–5905.
   PubMed Web of Science ®Google Scholar
• Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 Apr;27(4):382–392.
   PubMed Web of Science ®Google Scholar
• Jaafari N, Hua G, Adelaide J, et al. Expression of the tachykinin receptor mRNAs in healthy human colon. Eur J Pharmacol. 2008 Dec 3;599(1–3):121–125.
   PubMed Web of Science ®Google Scholar
• Houghton LA, Cremonini F, Camilleri M, et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil. 2007 Sep;19(9):732–743.
   PubMed Web of Science ®Google Scholar
• Prague JK, Abbara A, Comninos AN, et al. Neurokinin 3 receptor antagonists do not increase FSH or estradiol secretion in menopausal women. J Endocr Soc. 2020 Feb 1;4(2):bvz009.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007 Aug 4;335(7613):239.
   PubMedGoogle Scholar
• Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001 Dec 1;19(23):4280–4290.
   PubMed Web of Science ®Google Scholar
• Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 Dec;27(12):1350–1356.
   PubMed Web of Science ®Google Scholar
• Bushmakin AG, Abraham L, Pinkerton JV, et al. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. Menopause. 2014 Aug;21(8):815–822.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Astellas initiates phase 3 clinical trials for fezolinetant in postmenopausal women with vasomotor symptoms. Press Release. August 6, 2019.
   Google Scholar
• Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the women’s health initiative study results. Menopause. 2018 Dec 21;26(6):588–597.
   PubMed Web of Science ®Google Scholar
• Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas. 2014 Nov;79(3):287–291.
   PubMed Web of Science ®Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013 Oct;20(10):1027–1035.
   PubMed Web of Science ®Google Scholar
• Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas. 2010 Aug;66(4):333–343.
   PubMed Web of Science ®Google Scholar
• Mintziori G, Lambrinoudaki I, Goulis DG, et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms. Maturitas. 2015 Jul;81(3):410–413.
   PubMed Web of Science ®Google Scholar
• te Beek ET, Hay JL, Bullman JN, et al. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers. Br J Clin Pharmacol. 2012;75(5):1328–1339.
   Web of Science ®Google Scholar
• Cross R. Bayer to acquire KaNDy Therapeutics. Chemi Eng News 2020 98(31).
   Web of Science ®Google Scholar
• Trower M, Anderson RA, Ballantyne E, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020 Feb 17;27(5):498–505.
   PubMed Web of Science ®Google Scholar
• Wils J, Duparc C, Cailleux AF, et al. The neuropeptide substance P regulates aldosterone secretion in human adrenals. Nat Commun. 2020 May 29;11(1):2673.
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 6;389(10081):1809–1820.
   PubMed Web of Science ®Google Scholar
• Modi M, Dhillo WS. Neurokinin B and neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes. Semin Reprod Med. 2019 May;37(3):125–130.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Cormier J, Thieroff-Ekerdt R, et al. Pharmacodynamic activity of the novel neurokinin-3 receptor antagonist SJX-653 in healthy men. J Clin Endocrinol Metab. 2020 Dec 1; 105(12):e4857-e4865.
   Google Scholar
• License Agreement between Hoffmann-La Roche and Millendo Therapeutics. [cited 2021 March 15]. Available from: https://www.sec.gov/Archives/edgar/data/1544227/000155837019007932/mlnd-20190630ex104d45207.htm
   Google Scholar
• Business Wire Press Release. Millendo Therapeutics Provides Pipeline and Business Update. [cited 2021 March 15]. Available from: https://www.businesswire.com/news/home/20210105005561/en/Millendo-Therapeutics-Provides-Pipeline-and-Business-Update.
   Google Scholar
• Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017 Jan;52:82–90.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3647–3661.
   PubMed Web of Science ®Google Scholar